Tag Archives: Allergan

Financial Daily Dose 11.13.2019 | Top Story: Buffeted by Changing Consumer Demands, Dean Foods Declares Bankruptcy

BY: Michael D. Reif | November 13, 2019

Dean Foods, the largest milk company in the U.S., has filed for bankruptcy protection, a “fresh setback to a U.S. dairy industry struggling against declining U.S. milk consumption and rising competition.”  Industry experts have noted that the company’s attempts to streamline in recent years haven’t kept up with declining sales, making yesterday’s announcement close to … Continue reading

Financial Daily Dose 10.1.2019 | Top Story: Credit Suisse COO Resigns in Wake of Corporate Spying Scandal

BY: Michael D. Reif | October 1, 2019

Top Tidjane Thiam ally Pierre-Olivier Bouee, Credit Suisse’s COO, has resigned in the wake of an internal probe finding that he “ordered the surveillance of the bank’s former wealth-management chief, Iqbal Khan, without discussing it with Mr. Thiam or other senior bank officials.” Khan left Credit Suisse to join rival UBS Group today – WSJ … Continue reading

Financial Daily Dose 6.26.2019 | Top Story: US Tech Firms Find Ways to Resume Sales to Huawei

BY: Michael D. Reif | June 26, 2019

Some U.S. tech firms are finding ways to get around the White House’s Huawei no fly zone, with Micron, Qualcomm, and Intel leading the way – Bloomberg and NYTimes and WSJ Meanwhile, a more cautious Chinese consumer appears to be weakening President Xi’s hand as he prepares to talk trade with the U.S. on the … Continue reading

Financial Daily Dose 6.25.2019 | Top Story: Allergan and AbbVie Combine Forces in $63 Billion Deal

BY: Michael D. Reif | June 25, 2019

Massive pharma news to start the day, with AbbVie announcing that it’s reached a deal to buy Allergan for roughly $63 billion. The tie-up is seen as giving AbbVie a “dominant position in the $8 billion-plus market for Botox and other beauty drugs” is it “braces for the end of patent protection for the world’s … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | June 1, 2016

All of us are entitled to a change of heart. But when you’re one of the world’s most famous activist investors and the change involves a decent-sized stake in a drug maker (Allergan) that just 5 months ago was mixed up with a target of your serious criticism (that would be the ill-fated Pfizer/Allergan deal), … Continue reading